AlzeCure gets Approval to Start Phase II Clinical Trial with Non-opioid Pain Project ACD440 - Seite 2

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets other types of severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase and is continually working on business development to find suitable solutions for license agreements with other pharmaceutical companies.

FNCA Sweden AB, [phone] [e-mail], is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se

About neuropathic pain
Neuropathic pain affects approximately 7-8 percent of the total adult population, corresponding to roughly 600 million people globally. Some patients, with indications such as diabetes and HIV, are affected to a greater extent, where approximately 25 and 35 percent respectively of the patients experience neuropathic pain.

Peripheral neuropathic pain is the result of various types of damage to the nerve fibers, such as toxic, traumatic or nerve compression injuries as well a metabolic and infectious diseases. Common symptoms are painful tingling that can be described as "pins and needles", or choking or burning pain, as well as the feeling of getting an electric shock. Patients may also experience allodynia (pain caused by a stimulus that usually does not cause pain) or hyperalgesia (increased pain from a stimulus that normally provokes pain).

The market for neuropathic pain is characterized by a major medical need in all indications and in all major markets, where about 70-80 percent of patients do not get effective pain relief with existing treatment. The patient population will grow, among other things, due to an aging population and increased number of long-term cancer survivors and increasing prevlance of type-2 diabetes. The global market for neuropathic pain was valued at $11 billion in 2020 and is expected to grow to $25 billion by 2027.

Image Attachments

Martin Jönsson CEO AlzeCure Pharma

Attachments

AlzeCure gets approval to start Phase II clinical trial with non-opioid pain project ACD440

SOURCE: AlzeCure Pharma

View source version on accesswire.com:
https://www.accesswire.com/702645/AlzeCure-gets-Approval-to-Start-Phas ...